Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial [0.03%]
一项关于针对HIV感染人群的成人体专用肺炎球菌结合疫苗V116（STRIDE-7研究）的安全性、耐受性和免疫原性的国际多中心三期临床试验两部分并行分组随机对照试验
Jayani Pathirana,Moti Ramgopal,Charlotte Martin et al.
Jayani Pathirana et al.
Background: People living with HIV are at high risk of pneumococcal disease, and evidence of pneumococcal conjugate vaccine (PCV) safety and efficacy is needed. We aimed to evaluate the safety, tolerability, and immunogen...
Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysis [0.03%]
长效注射用卡博特格拉维作为暴露前预防的动态选择HIV预防法在东非、中非、南非和西非的成本效益模型分析
Andrew N Phillips,Matthew D Hickey,Starley B Shade et al.
Andrew N Phillips et al.
Background: In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention (DCP) intervention that offered structured choice of biomedical prevention product and opportunity to change products over t...
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial [0.03%]
人类免疫缺陷病毒相关新型隐球菌性脑膜炎患者Epstein-Barr病毒和巨细胞病毒共感染与死亡率风险：AMBITION-CM随机对照试验中前瞻性套叠队列的事后分析
Jayne Ellis,Elisabetta Groppelli,Ronan Doyle et al.
Jayne Ellis et al.
Background: HIV-associated cryptococcal meningitis case fatality remains greater than 25%. Co-prevalent infections might contribute to poor outcomes. We aimed to ascertain the prevalence and the clinical significance of E...
HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis [0.03%]
抗逆转录病毒治疗的儿童和青少年与人类免疫缺陷病毒感染相关的死亡率时间趋势：按年龄、治疗持续时间和地区划分的系统评价和荟萃回归分析
Jiawei He,Edmond Brewer,Amanda Novotney et al.
Jiawei He et al.
Background: Past cohort studies have examined mortality among children and young adolescents (aged 0-14 years) who have received antiretroviral therapy (ART), but no systematic reviews have been undertaken to synthesise t...
Stephan Rabie,Hlombekazi Sybil Majokweni,Lwandile Tokwe et al.
Stephan Rabie et al.
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era [0.03%]
亲代联合抗逆转录病毒治疗时代HIV暴露未感染婴儿的免疫学特征
Melanie A Gasper,Anna-Ursula Happel,Sonwabile Dzanibe et al.
Melanie A Gasper et al.
The introduction and programmatic scale-up of universal antiretroviral therapy in pregnancy (option B and option B+) and the subsequent universal test-and-treat approaches have dramatically reduced infant HIV-1 acquisitions globally, with a...
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial [0.03%]
比克恩丙胺、恩曲他滨和特诺福韦阿拉芬酰胺片对比利托那韦增强的蛋白酶抑制剂类抗逆转录病毒疗法治疗海地二线治疗方法成功实现病毒学抑制的HIV患者：一项开放标签非劣效性随机试验
Patrice Severe,Samuel Pierre,Fabienne Homeus et al.
Patrice Severe et al.
Background: Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is sca...
Randomized Controlled Trial
The lancet. HIV. 2025 Sep;12(9):e616-e626. DOI:10.1016/S2352-3018(25)00130-4 2025
Peter Hayward
Peter Hayward